Novartis AG Stock News

Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a pure-play innovative medicines “powerhouse.” H

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

Bristol Myers is turning to acquisitions and its pipeline to offset a major patent cliff. Novartis just completed a spinoff that should lead to stronger overall growth.

The latest trading day saw Novartis (NVS) settling at $97.87, representing a -1.55% change from its previous close.

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-

UK-based biotech firm AstronauTx has secured £48 million ($61 million) in a significant Series A funding round, marking a step towards developing treatments for Alzheimer's and other neurodegenerativ

Novartis (NVS) closed at $97.14 in the latest trading session, marking a +1.03% move from the prior day.

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA v

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started tradi

Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest develop

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.